Current status of cancer vaccines and whether Lynch syndrome is an ideal disease for cancer immunotherapy

Usama Abdul Karim1, Sundas Iqbal1, Mustaqeem khan2, Muhammad Usman Bhatti1, Mostafa el mohamady mostafa el mohalawy3, Zameel Saleem4, Shoaib Waris4

1Minhaj university Lahore, 2University of Malakand, 3Damanhor university, Egypt, 4University of Sialkot, Punjab


There are more than 100 different types of cancer. Almost anywhere in the body, it can manifest itself. It occurs when genes that control cell activity mutate, resulting in abnormal cells that divide and multiply, eventually causing your body to malfunction. T lymphocyte-based cancer immunotherapies have emerged as a primary objective for activating the body’s defenses against cancer by the immune system. Cancer vaccinology, adoptive cellular therapy, and the capacity of T cells to promote checkpoint blockade. The immune system is boosted by cancer vaccines to attack cancer cells. In cancer immunotherapy, these advancements necessitate the development of personalized recombinant vaccines with low side effects and high efficacy. Lynch Syndrome (LS) is a genetic condition that is autosomal dominant and has a high risk of colorectal cancer. Mismatch repair (MMR) deficiency causes genetic instability, which is the hallmark of LS. In contrast, Lynch syndrome is an ideal point for assessing the viability and efficiency of vaccination-based cancer treatment. The advanced development of bioinformatics and next-generation sequencing technologies has made it possible to quickly identify and predict tumor-specific neoantigens. In this study, we demonstrated that cancer immunotherapies have emerged as a key objective for involving the immune system in the fight against cancer.